Home › Funds › Madison Avenue Partners, LP › RARE
Madison Avenue Partners, LP position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
Madison Avenue Partners, LP reported holding 1,705,351 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q3 2026 13F filing — a position valued at US$25.6M, representing 1.02% of its reported portfolio and ranking #20 among its reported holdings. Madison Avenue Partners, LP first reported this position in Q3 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Madison Avenue Partners, LP's RARE position evolved
Madison Avenue Partners, LP first disclosed a stake in RARE in Q3 2026 at 1,705,351 shares (US$25.6M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 1.71M | $25.63M | New |
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 21 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$128.2M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M), Bellevue Group AG (US$66.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 8.53M sh · $128.20M · Q3 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
- Nantahala Capital Management, LLC 2.34M sh · $35.16M · Q3 2026
More on Madison Avenue Partners, LP
FAQ
How long has Madison Avenue Partners, LP held RARE?
Madison Avenue Partners, LP has disclosed RARE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Madison Avenue Partners, LP's current position in RARE?
As of Q3 2026, Madison Avenue Partners, LP holds 1.71M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $25.63M, representing 1.02% of its reported portfolio and ranking #20.
Has Madison Avenue Partners, LP been buying or selling RARE?
In the latest 13F filing (Q3 2026), Madison Avenue Partners, LP newly opened its position in RARE.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, FRONTIER CAPITAL MANAGEMENT CO LLC, Bellevue Group AG, among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.